Abstract
Johnson & Johnson's operating activities are conducted within three business
segments: Medical Devices & Diagnostics, Pharmaceutical and Consumer. This
report provides a full review of the company's pharmaceutical activities.
Johnson & Johnson, through more than 230 operating companies, manufactures and
sells a broad range of products in the healthcare field for the
pharmaceutical, consumer, and medical devices and diagnostic markets to most
countries of the world. The company is organised on the principles of
decentralised management.
Current Growth Drivers
Within the Pharmaceutical segment in 2005, strong sales performances were
demonstrated by Risperdal and Risperdal Consta, Remicade, Topamax and Levaquin.
Key Late-Stage Products
Virology is a relatively new area of focus for J&J and it is currently
developing three HIV compounds of which TMC114, the most advanced compound,
has been filed. Candidates in Phase III trials include:
- Ceftobiprole for complicated skin and skin structure infections and
nosocomial pneumonia. Both indications have been granted fast track
designation by the FDA.
- Doripenem, a broad-spectrum antibiotic for complicated urinary tract
infections, complicated intra-abdominal infections and nosocomial pneumonia.
- BAY 59-7939 (Factor Xa inhibitor) for venous thromboembolism prevention
after major orthopaedic surgery (hip and knee).
View Cart
